These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7495096)

  • 21. A haemophilia B patient with severe burn injury: increased requirement for factor IX replacement therapy associated with venous thromboembolism.
    Yaish H; Rodgers GM
    Haemophilia; 2008 May; 14(3):607-9. PubMed ID: 18194306
    [No Abstract]   [Full Text] [Related]  

  • 22. Myocardial infarction during factor IX infusion in hemophilia B: case report and review of the literature.
    Najaf SM; Malik A; Quraishi AU; Kazmi K; Kakepoto GN
    Ann Hematol; 2004 Sep; 83(9):604-7. PubMed ID: 15205916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The manufacturing process for recombinant factor IX.
    Harrison S; Adamson S; Bonam D; Brodeur S; Charlebois T; Clancy B; Costigan R; Drapeau D; Hamilton M; Hanley K; Kelley B; Knight A; Leonard M; McCarthy M; Oakes P; Sterl K; Switzer M; Walsh R; Foster W
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):4-10. PubMed ID: 9565160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of preparation PPSB on coagulation and hemostasis in hemophilia B patients].
    Tarasova LN; Sadkov SA; Porokhnenko SG
    Gematol Transfuziol; 1984 Aug; 29(8):22-4. PubMed ID: 6479558
    [No Abstract]   [Full Text] [Related]  

  • 25. Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B.
    Brooks MB; Gu W; Ray K
    J Am Vet Med Assoc; 1997 Dec; 211(11):1418-21. PubMed ID: 9394892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preparation and properties of a therapeutic factor IX concentrate.
    Suomela H; Myllylä G; Raaska E
    Vox Sang; 1977 Jul; 33(1):37-50. PubMed ID: 883244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 28. Preclinical studies of recombinant factor IX.
    Schaub R; Garzone P; Bouchard P; Rup B; Keith J; Brinkhous K; Larsen G
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):28-32. PubMed ID: 9565164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with a Swedish factor IX concentrate.
    Nilsson IM; Ahlberg A; Björlin G
    Acta Med Scand; 1971 Oct; 190(4):257-66. PubMed ID: 5137259
    [No Abstract]   [Full Text] [Related]  

  • 30. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract]   [Full Text] [Related]  

  • 31. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical characterization of recombinant factor IX.
    Bond M; Jankowski M; Patel H; Karnik S; Strang A; Xu B; Rouse J; Koza S; Letwin B; Steckert J; Amphlett G; Scoble H
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):11-7. PubMed ID: 9565161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Action of venom of the central Asian cobra (Naja oxiana eich.) on the blood-coagulating system].
    Mitel'man LSh
    Biull Eksp Biol Med; 1966 Sep; 62(9):69-71. PubMed ID: 6012423
    [No Abstract]   [Full Text] [Related]  

  • 34. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
    Liles D; Landen CN; Monroe DM; Lindley CM; Read MS; Roberts HR; Brinkhous KM
    Thromb Haemost; 1997 May; 77(5):944-8. PubMed ID: 9184407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current management of hemophilia B.
    Roberts HR; Eberst ME
    Hematol Oncol Clin North Am; 1993 Dec; 7(6):1269-80. PubMed ID: 8294316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple substitutions at single site: interpreting the effect of Asn92 mutations in human coagulation factor IX.
    Sharma A; Chavali S; Mahajan A; Biswas P; Bharadwaj D
    Haemophilia; 2008 Mar; 14(2):396-9. PubMed ID: 18179572
    [No Abstract]   [Full Text] [Related]  

  • 37. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor IX of the blood coagulation system: a review.
    Taran LD
    Biochemistry (Mosc); 1997 Jul; 62(7):685-93. PubMed ID: 9331959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
    Djulbegovic B; Marasa M; Pesto A; Kushner GM; Hadley T; Joseph G; Goldsmith G
    Am J Hematol; 1996 Feb; 51(2):168-70. PubMed ID: 8579061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.